Civil society organisations and health activists are urgently calling for a comprehensive overhaul of India's National List of Essential Medicines (NLEM), citing outdated inclusions and critical omissions that are hampering access to affordable and effective healthcare for millions.
The NLEM, first published in 1996 and last revised in 2015, serves as a crucial guide for policymakers, pharmaceutical companies, and healthcare providers by identifying a core set of medicines deemed essential for public health. However, critics argue that the current list has failed to keep pace with medical advancements and the evolving disease burden in India. Specific concerns include the continued inclusion of older, less effective drugs, while newer, life-saving medications, particularly for non-communicable diseases and emerging health threats, remain absent or inaccessible due to cost. This disparity impacts patient care, increases out-of-pocket expenditure, and challenges the government's goal of universal health coverage.
The demand for revision is amplified by the global context of pharmaceutical innovation and the varying accessibility of medicines worldwide. India, often referred to as the 'pharmacy of the world,' plays a pivotal role in global drug manufacturing and supply. A robust and current NLEM is not only vital for domestic health security but also influences drug pricing and availability internationally. Health groups emphasize that updating the list is a critical step towards ensuring that India's vast population benefits from the latest medical breakthroughs and receives the most appropriate and cost-effective treatments available.
With the next revision reportedly in the works, what specific changes do you believe are most crucial for India's National List of Essential Medicines to ensure equitable and effective healthcare access?